Posted in | Nanomedicine

Titan Spine’s FDA-Cleared nanoLOCK Surface Technology Wins Orthopedics This Week’s 2015 Spine Technology Awards

Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it has been recognized as a winner of Orthopedics This Week’s 2015 Spine Technology Awards in the Biomaterials and Biologics category. Furthermore, Titan Spine’s nanoLOCK™ surface technology, the only FDA-cleared nanotechnology for the spine, scored highest of all products submitted.

Each year, the publication rewards exemplary and innovative spine surgery products and the engineering teams and inventors who create them.1

Titan Spine’s nanoLOCK™ surface technology was awarded the Spine Technology Award as it met several criteria, including creativity and innovation; long-term significance to the problem of treating spinal diseases; providing a solution to a current clinical problem; potential to improve the standard of care; cost-effectiveness; and consumer attractiveness. These criteria are then adjudicated by a panel of spine surgeons from around the country.

Titan Spine will be recognized at the 2015 North American Spine Society (NASS) Annual Meeting, taking place October 14-17 in Chicago, IL.

“We are very pleased to have our unique nanoLOCK™ surface technology recognized as one of the top spine technologies of 2015,” commented Andrew Shepherd, Vice President of Marketing for Titan Spine. “It validates the potential impact that nanoLOCK™ can have on our surgeons and patients, and it further separates Titan from several of our competitors that claim to have nanotechnology but are not FDA cleared to do so.”

The full line of Endoskeleton® devices features Titan Spine’s proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and cellular levels created by a subtractive process. This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), and creating the potential for a faster and more robust fusion.2,3

Note:
1 Entry Guidelines. Orthopedics this Week 2015 Technology Awards. 2015. Web.
2 Olivares-Navarrete, R., Gittens, R.A., Schneider, J.M., Hyzy, S.L., Haithcock, D.A., Ullrich, P.F., Schwartz, Z., Boyan, B.D. (2012). Osteoblasts exhibit a more differentiated phenotype and increased bone morphogenetic production on titanium alloy substrates than poly-ether-ether-ketone. The Spine Journal, 12, 265-272.
3 Olivares-Navarrete, R., Hyzy, S.L., Gittens, R.A., Schneider, J.M., Haithcock, D.A., Ullrich, P.F., Slosar, P. J., Schwartz, Z., Boyan, B.D. (2013). Rough titanium alloys regulate osteoblast production of angiogenic factors. The Spine Journal, 13, 1563-1570.

Source: http://www.titanspine.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit